Thyroid nodules represent a common disease, as they are palpated at an average rate of 3%-7% of normal adults, 1,2 and they are diagnosed at a rate of about 20%-76% during thyroid ultrasonography. 3, 4 Most thyroid nodules are benign and fewer than 5% of these nodules are malignant. [3] [4] [5] It has been recently reported that the incidence rate of thyroid cancer is dramatically increasing worldwide, and the rise in South Korea is so high that thyroid cancer has ranked at the top in terms of the cancer incidence rate in women as of 2011. In the diagnosis of thyroid nodules, ultrasound (US)-guided Objectives: Ultrasound-guided fine-needle aspiration (FNA) is routinely used in the evaluation of thyroid nodules. However, it has several pitfalls, as has been noted in nondiagnostic and indeterminate cases. This study aims to investigate the value of BRAF V600E mutation co-testing in FNA cytology. Method: A total of 310 patients underwent BRAF V600E mutation co-testing in FNA cytology on thyroid nodules between June 2013 and June 2014. Of the 310 patients, 69 patients who had undergone a surgery for thyroid nodules were included in this study. The presence of the BRAF V600E mutation was determined by allele-specific polymerase chain reaction amplification of exon 15 of the BRAF gene. Results: Of 69 cases, 33 (47.8%) were BRAF V600E mutation positive. The BRAF V600E mutation was not significantly associated with high-risk features such as tumor size, lymph node metastasis, and pathological stage. The respective diagnostic performance of FNA (P = 0.02), BRAF V600E mutation (P = 0.03), and ultrasonographic (P = 0.00) findings was statistically significant. The sensitivity, specificity and positive predictive value of FNA was 64.9%, 83.3%, and 94.8%. The sensitivity, specificity and positive predictive value of BRAF V600E mutation was 56.1%, 91.7%, and 96.9% and the US features was 91.2%, 91.7%, and 98.1% respectively. However, sensitivity of FNA with BRAF V600E mutation (77.2%) was lower than FNA with US (92.9%) and combination all together (92.9%). Conclusion: In this study, we found that US features were the most useful in preoperative differential diagnosis of thyroid nodules. BRAF V600E mutation co-testing in FNA cytology was also useful for diagnosis of thyroid tumors.
fine-needle aspiration (FNA) is a simple, accurate, and cheap method, but it is non-diagnostic in 30%-45% of cases, while atypical follicular lesions of undetermined significance (AUS), suspected follicular carcinoma, or Hurthle cell carcinoma may not be diagnosed by FNA. 6 Thyroid ultrasonography, which plays an important role in the diagnosis and treatment of thyroid diseases, is the standard and most recommended test method for thyroid nodules. 7 Clinical studies have shown various parameters for the determination of malignancy on the basis of ultrasonographic findings. The specific ultrasonographic finding of benign thyroid nodules is the spongiform appearance of multiple microcystic components separated by thin septa inside thyroid nodules; the specificity of the finding is 99.7%-100%. 8 The findings that suggest malignant nodules include thyroid nodules that are taller (rather than wide) in appearance, spiculate boundaries, a marked hypoechoic shadow, microcalcifications, and extracapsular invasion. Among these findings, the specificity of thyroid nodules that are taller, rather than wide, in appearance is 93%; that of spiculate boundaries is 92%, that of marked hypoechoic shadow is 92%-94%, and that of microcalcification is 86%-95%. Moreover, about 70%-90% of thyroid nodules may be differentiated if the parameters of ultrasonography are used at a positive predictive value of 42%-94%. 8, 9 With the recent development of molecular bio- Raf kinase is an important factor in the signaling pathway, Ras → Raf → MAPK kinase → ERK/MAPK, involved in the growth, differentiation, and proliferation of cells. Among the various isotypes of Raf kinase, the B type RAF (BRAF) is the most powerful activator of the MAPK signaling pathway, and the gene of the B type RAF (BRAF) is located on chromosome 7. 11 BRAF V600E , which is the most common mutation of BRAF, accounts for 90% of BRAF mutations; it is caused by the transversion of the 1799 nucleotide on exon 15 of the gene from thymine to adenine. 12 Among thyroid carcinomas, the BRAF V600E mutation is particularly common in thyroid papillary carcinoma, and it is most frequently expressed in conventional papillary carcinoma among the various subtypes of papillary carcinomas.
It has been reported that with respect to thyroid cancer, Koreans shows a higher incidence rate of papillary carcinomas and a higher positive response rate of BRAF V600E in comparison with other countries. 13 Since it has been known that the BRAF V600E mutation is specific to papillary carcinoma, and given that it is highly correlated with the 
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RESULTS
Comparison of the Presence of BRAF V600E and FNA with Histopathologic Examination Results
Of the 69 cases that were included in this study, (Table 1) .
Correlation between the BRAF V600E Mutation and
Various Clinicopathological Parameters in
Papillary Thyroid Carcinomas
There was no significant difference in the expression of the BRAF V600E mutation in papillary thyroid carcinoma with respect to either the subject's age group or sex. No significant difference was found in the size of the carcinoma. Nodule calcification was observed in 19 cases (61.3%) of the BRAF V600E mutation positive group, while it was observed only in eight cases (34.8%) of the BRAF V600E mutation negative group, indicating that there was a significant difference between the two groups (P = 0.04). None the findings were associated with any of the factors that impact thyroid cancer prognosis (including extrathyroidal invasion, lymph node metastasis, and TNM stage); these factors were also not correlated with the presence of the BRAF V600E mutation ( Table 2) .
Comparison of Diagnostic Ability among FNA, BRAF V600E Mutation, and Ultrasonographic
Findings
The sensitivity, specificity, and positive predictive value of FNA were 64.9%, 83.3%, and 94.8%, respectively, and those of the BRAF V600E mutation test were 56.1%, 91.7%, and 96.9%, respectively.
The BRAF V600E mutation test showed a lower sensitivity and a higher specificity when compared with FNA. The sensitivity, specificity, and positive predictive value of ultrasonographic findings were 91.2%, 91.7%, and 98.1%, respectively, all of which were higher than those of an independent FNA and an independent BRAF V600E mutation test. All three test methods, FNA (P = 0.02), ultrasonography (P = 0.00), and the BRAF V600E mutation test (P = 0.03), were significant in terms of their ability to differentiate between a malignant carcinoma and a benign carcinoma found by histopathologic examination ( Table 3) .
Comparison of Diagnostic Ability between a
Combination of FNA and the BRAF V600E
Mutation and a Combination of FNA and
Ultrasonographic Findings
The sensitivity, specificity, and positive predictive value of the combination of FNA and the BRAF V600E mutation test were 77.2%, 75.0%, and 93.6%, respectively, indicating that the sensitivity was higher and the specificity was lower in comparison with independently performed FNA and the BRAF V600E mutation test. The sensitivity, specificity, and positive predictive value of the combination of FNA and ultrasonographic findings were 92.9%, 83.3%, and 96.3%, respectively, indicating that the specificity was lower than that of independent ultrasonography (Table 3 ).
DISCUSSION
Since it was first attempted by Lipton et al. 16 in 1944 for a case of thyroid disease, FNA has It is well known that the positive predictive value of the BRAF V600E mutation test in combination with FNA is known to be 99% or higher. 23 In the present reported that they were 93.8%, 66.0%, and 56.1%, respectively. In the present study, the sensitivity, specificity, and positive predictive value of ultrasonography were 91.2%, 91.7%, and 98.1%, respectively, indicating that the sensitivity and specificity were higher than those of previous studies.
The sensitivity and specificity of these ultrasonographic findings were higher than those of the FNA test and the BRAF V600E mutation test, which showed that ultrasonographic findings are important in the diagnosis of thyroid nodules. The sensitivity of the combination of FNA, ultrasonographic findings, and the BRAF V600E mutation test was 98.2% in the study by Moon et al. 24 and 96.2% in the investigation by Seo et al. 25 In this study, the sensitivity of the combination of FNA, ultrasonographic findings, and the BRAF V600E mutation test was 92.9%. This result demonstrates the im-portance of ultrasonographic findings.
In conclusion, the present study showed that ultrasonographic findings were most helpful in providing a differential diagnosis of preoperative thyroid cancer. Furthermore, combining the BRAF V600E mutation test with US-guided FNA may be clinically helpful, particularly since a positive response on the BRAF V600E mutation test in combination with US-guided FNA is indicative of malignancy.
